Skip to main content
Equibles

CITADEL ADVISORS LLC

Position in ZVRA — Zevra Therapeutics, Inc.

CIK 1423053 MIAMI, FL
Back to ZVRA Full portfolio

Position in ZVRA

as of Mar 31, 2026 · filed May 15, 2026
Position Value
$5,840,834
-$1,711,136 QoQ
Shares Held
626,699
-25.6% QoQ
Ownership
1.06%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2021
21 quarters on record
Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Common Shares in ZVRA Over Time

Shares Held

Position Value (USD)

Derivatives in ZVRA

reported options exposure · as of Mar 31, 2026
CallValue
$2,268,488
CallShares
243,400
PutValue
$391,440
PutShares
42,000

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Mar 31, 2026

CITADEL ADVISORS LLC holds $5,784,241,435 across 374 Biotechnology names. ZVRA ranks #119 (0.1% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 INSM
INSMED Inc
 2,182,571 $356,894,009
2 ONC
BeOne Medicines Ltd.
 1,032,298 $306,561,536
3 BMRN
Biomarin Pharmaceutical Inc
 4,512,634 $254,918,694
4 JAZZ
Jazz Pharmaceuticals plc
 1,259,444 $238,097,887
5 MDGL
Madrigal Pharmaceuticals, Inc.
 453,843 $237,573,195
6 BBIO
BridgeBio Pharma, Inc.
 3,173,940 $235,696,783
7 TERN
Terns Pharmaceuticals, Inc.
 3,218,810 $169,695,662
8 PTGX
Protagonist Therapeutics, Inc
 1,551,900 $163,570,260

All Filings in ZVRA

Export CSV
50 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $5,840,834 626,699
2026-03-31 $2,268,488 243,400
2026-03-31 $391,440 42,000
2025-12-31 $7,551,970 842,854
2025-12-31 $1,408,512 157,200
2025-12-31 $501,760 56,000
2025-09-30 $1,823,979 191,796
2025-09-30 $970,971 102,100
2025-09-30 $1,137,396 119,600
2025-06-30 $607,009 68,900
2025-06-30 $1,006,691 114,267
2025-03-31 $29,211 3,900
2025-03-31 $1,863,751 248,832
2025-03-31 $695,072 92,800
2024-12-31 $20,758 2,489
2024-12-31 $701,394 84,100
2024-12-31 $200,994 24,100
2024-09-30 $926,490 133,500
2024-09-30 $298,420 43,000
2024-09-30 $471,288 67,909
2024-06-30 $515,666 105,238
2024-06-30 $87,220 17,800
2024-06-30 $98,000 20,000
2024-03-31 $1,885 325
2024-03-31 $166,837 28,765
2024-03-31 $91,640 15,800
2023-12-31 $2,192,789 334,777
2023-12-31 $557,830 85,165
2023-12-31 $260,035 39,700
2023-09-30 $808,168 167,670
2023-09-30 $151,830 31,500
2023-09-30 $319,566 66,300
2023-06-30 $242,250 47,500
2023-06-30 $431,970 84,700
2023-06-30 $145,048 28,441
2023-03-31 $502,150 91,300
2023-03-31 $171,523 31,186
2023-03-31 $577,500 105,000
2022-12-31 $1,116,747 243,300
2022-12-31 $348,381 75,900
2022-12-31 $499,667 108,860
2022-09-30 $1,418,352 227,300
2022-09-30 $1,663,584 266,600
2022-06-30 $1,102,958 247,300
2022-06-30 $1,120,352 251,200
2022-03-31 $1,678,511 333,700
2022-03-31 $1,272,087 252,900
2021-12-31 $207,410 23,813
2021-12-31 $2,175,758 249,800
2021-12-31 $3,536,260 406,000

Report a Problem

Category
Description
Email (optional, for follow-up)